Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 2, 2015, Pages 1158-1167

  Sulzbacher, Florian ^a,b   Roberts, Philipp ^a,b   Munk, Marion R ^a   Kaider, Alexandra ^a   Kroh, Maria Elisabeth ^a   Sacu, Stefan ^a,b   Schmidt Erfurth, Ursula ^a,b   Eibenberger, Katharina ^b   Schütze, Christopher ^b   Rezar, Sandra ^b   Schlanitz, Ferdinand ^b   Schmidinger, Gerald ^b   Pircher, Niklas ^b   Ritter, Markus ^b   Leodolter, Anna ^b   Reitner, Andreas ^b   Pemp, Berthold ^b   Funk, Marion ^b   Pollreisz, Andreas ^b   Chen, Ying Ting ^b   Prager, Sonja ^b   Deak, Gabor ^b   Kriechbaum, Katharina ^b   Lammer, Jan ^b   Mitsch, Christoph ^b   Baratsits, Magdalena ^b   Jakob, Astrid ^b   Kefer, Katharina ^b   Kroh, Maria ^b   Mittermüller, Jasmin ^b   Ender, Marie Kristine ^b   Koizar, Lisbeth Bobich ^b   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Microperimetry; Neovascular AMD; Spectral domain OCT

Indexed keywords

AFLIBERCEPT; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; B SCAN; CLINICAL ARTICLE; EXTERNAL LIMITING MEMBRANE; EYE PHOTOGRAPHY; FEMALE; HUMAN; MORPHOLOGY; PERIMETRY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA NEOVASCULARIZATION; RETINA NEUROEPITHELIAL LAYER; SENSITIVITY ANALYSIS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; VISION; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA; RETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL NEOVASCULARIZATION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84925373062     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14298     Document Type: Article

References (33)

1. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009;116:15–23
2. Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120: 2630–2636
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
4. Brown DM, Michels M, Kaiser PK, et al.; for the ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study. Ophthalmology. 2009;116: 57–65
5. Busbee BG, Ho AC, Brown DM, et al.; for the HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–1056
6. IVAN Study Investigators, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular agerelated macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–1411
7. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398
8. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet agerelated macular degeneration. Ophthalmology. 2012;119: 2537–2548
9. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW Studies. Ophthalmology. 2014;121:193–201
10. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185
11. Bolz M, Simader C, Ritter M, et al. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2010;94:185–189
12. Charbel Issa P, Troeger E, Finger R, et al. Structure-function correlation of the human central retina. PLoS One. 2010;22: e12864
13. Schmidt-Erfurth U, Eldem B, Guymer R, et al.; for the EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118: 831–839
14. Sulzbacher F, Kiss C, Kaider A, et al. Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53: 6448–6455
15. Sulzbacher F, Kiss C, Kaider A, et al. Correlation of OCT characteristics and retinal sensitivity in neovascular age-related macular degeneration in the course of monthly ranibizumab treatment. Invest Ophthalmol Vis Sci. 2013;54:1310–1315
16. Chen FK, Patel PJ, Xing W, et al. Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci. 2009;50:3464–3472
17. Ritter M, Elledge J, Simader C, et al. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. Br J Ophthalmol. 2011;95:381–385
18. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175–1186
19. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32:434–457
20. Shin HJ, Chung H, Kim HC. Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration. Retina. 2013;33:964–970
21. Mathew R, Richardson M, Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular agerelated macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155:720–726
22. Seiple W, Rosen RB, Castro-Lima V, et al. The physics and psychophysics of microperimetry. Optom Vis Sci. 2012;89: 1182–1191
23. Acton JH, Smith RT, Greenberg JP, et al. Comparison between MP-1 and Humphrey visual field defects in glaucoma and retinitis pigmentosa. Optom Vis Sci. 2012;89:1050–1058
24. Wu Z, Ayton LN, Guymer RH, et al. Intrasession test-retest variability of microperimetry in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013;54:7378–7385
25. Ying GS, Huang J, Maguire MG, et al. Comparison of Agerelated Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122–129
26. Major JC, Wykoff CC, Mariani AF, et al. Comparison of spectraldomain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina. 2014;34:48–54
27. Iwata E, Ueno S, Ishikawa K, et al. Focal macular electroretinograms after intravitreal injections of bevacizumab for agerelated macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:4185–4190
28. Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti- VEGF therapy. Invest Ophthalmol Vis Sci. 2011;52:1599-1605
29. Pelosini L, Hull CC, Boyce JF, et al. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011;52: 2741–2748
30. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33:1605–1612
31. Brown DM, Chen E, Mariani A, et al. Super-dose Anti-VEGF (SAVE) Trial:2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration–primary end point. Ophthalmology. 2013;120:349–354
32. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156: 29–35, e2
33. Grunwald JE, Daniel E., Huang J, et al.; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121:150–161.